The cytosolic glutathione S-transferase (GST) enzymes serve as ideal biomarkers of organ damage as they exhibit many of the required characteristics, i.e. specific localisation, high cytosolic concentration and relatively short half-life. The role of GSTs as early indicators of organ damage is applicable to both human and animal models. Because of the regio-specific localisation of the different isoforms of GST in liver and kidney, simultaneous monitoring of classes of GSTs in biological matrices permits the identification of specific areas of damage within a particular organ. Immunoassays have been developed which quantify canine aGST and rodent vGST (Yb1). The immunoassays are solid phase EIAs, where GST in the sample or standard is captured by a specific anti-GST antibody coated onto the solid phase. After washing, a specific enzyme-labelled IgG conjugate is added which binds to the captured GST. After a further washing step, substrate is added and a colour developed. The absorbance is measured on an ELISA plate reader and is directly proportional to the amount of GST present in the sample. The assays are performed at room temperature and can be completed within 3 h. The immunoassays are specific for each GST and have a range of 0-100 vg/l. A range of assay parameters were investigated to validate the EIAs for GST detection. The assays are sensitive and reproducible. CV for inter-and intra-assay variation were below 9% for Yb1 assay and below 20% for the canine aGST EIA. Recovery of spiked GST over the standard curve range was 102 and 99%, respectively. No prozone effect was observed and samples exhibited linearity of dilution in both assays. Validation has shown that using these enzyme immunoassay, Yb1 and canine aGST can be measured accurately
Introduction
The glutathione S-transferases (GSTs) are a family of cytosolic enzymes involved in the detoxification of a range of xenobiotic compounds by conjugation to glutathione. The enzymes consist of homo-and heterodimers grouped into speciesindependent families: alpha (h), pi (y), mu (v) and theta (q) as well as a microsomal trimeric enzyme [1] .
In man, h-glutathione S-transferase (hGST) is the predominant GST isoform in the liver. The uniform hepatic distribution together with relatively high hepatic levels and a short plasma half-life ( 90 min) mean that this enzyme is more sensitive than the aminotransferases as an indicator of hepatocyte status following transplantation, drug-induced liver damage, hepatitis C infection and h-interferon therapy [2 -4] . It has recently been reported that monitoring hGST in the first 3 post-operative months after transplantation resulted in improved patient care and reduced mortality and morbidity [5] . Transplant recipients who had hGST reported to the ward, had fewer biopsies, a lower incidence of more severe rejection and fewer episodes of infection. Patients also had shorter stays in hospital post-operatively and better graft survival up to 100 days post-operation.
A similarly unique regio-specific distribution of hGST and yGST occurs in the kidney. hGST is located primarily in the proximal tubules, whereas yGST is present mainly in the distal tubule region of the nephron [6] . A number of different groups have been able to identify specific damage to the proximal or distal tubules in the kidney by monitoring urinary GST. One study looked at kidney damage resulting from the administration of the anaesthetic sevoflurane [7] . The authors were able to distinguish between proximal and distal tubular damage by the simultaneous analysis of urinary h and yGST. In another study, psoriasis patients who developed renal impairment while receiving Cyclosporin A (a known nephrotoxin which targets the proximal tubules of the kidney) also showed significantly increased urinary hGST prior to any increase in creatinine or glomular filtration rate (GFR) [8] .
Because of the world-wide shortage of organs for transplantation, there is an increasing demand for alternative sources of suitable grafts. Xenotransplantation has been suggested as one possible solution, but many practical as well as ethical problems have been associated with this area. Another option is the use of organs from non-heart beating donors (NHB). hGST has been successfully used to monitor the viability of NHB donor kidneys prior to transplantation [9] . These organs are obtained from NHB donors after final and irreversible cardiac arrest and undergo a period of warm ischemia. The duration of this period of ischemia is critical in determining the outcome of transplantation, as increased ischemia times may result in non-viable grafts. Since ischemia predominantly damages cells in the proximal tubules [10] , the monitoring of hGST can provide valuable information on the status of the organs prior to transplantation. There was a strong correlation between the release of hGST and the period of warm ischemia where high levels of hGST were associated with increased warm ischemia times and poor graft function. Thus, by monitoring hGST in the kidney perfusate during machine preservation, the functional outcome of NHB donor grafts can be predicted before transplantation, assisting in the selection of viable organs for transplantation. Levels of hGST can now be used to define reliable safety margins for viability of NHB kidneys.
The main function of the GST family of enzymes is the detoxification of xenobiotics. The protection imparted by these enzymes on the cells against potentially harmful electrophilic compounds is essential in the maintenance of normal healthy processes. However, GSTs have also been implicated in other areas, namely as indicators of malignant transformation and acquired resistance of cells to chemotheraputic drugs [11] .
There have been numerous publications on the increased expression of GST, in particular yGST, in the malignant transformation of a variety of cells and tissues including bladder [12] , head and neck [13] , colon [14] , ovarian [15, 16] and renal cell [17] . Associated with this increased expression of GST is the enhanced detoxification capability of the cell. This has serious implications for drug therapy as acquired resistance can seriously limit the effectiveness of clinically important anti-cancer drugs.
The distribution of GSTs in animal models follows a similar pattern to that in humans and thus they fulfil similar roles as early indicators of organ damage. hGST has been shown to be a more sensitive marker than the transaminases in the assessment of hepatocellular damage in isolated perfused rat livers [18] . In rats, vGST (Yb1) has been located to the distal convoluted tubule of the rat kidney, whereas hGST (YaYc) has been found in the proximal as well as the distal tubule [19] .
Compound A, a degradation product of the anaesthetic sevoflurane, was shown to cause an increase in urinary hGST in rats [20] . This increase was mirrored by an increase in proximal tubular cell necrosis, identified by histological examination. The measurement of Yb1 in urine has been shown to be an excellent indicator of nephrotoxicity or kidney damage caused by cisplatin [21] . Other nephrotoxic agents have also been shown to increase kidney Yb1 concentration [22, 23] .
GSTs have been identified in a number of canine tissues, including liver [24] and lens [25] . As in man, the liver has a high concentration of hGST and canine liver cytosolic GSTs have been purified, characterised and found to contain class v, h and y subunits, together with a possible q class subunit [26] .
Since enzyme activity assays do not readily facilitate differentiation between the various GST isoenzymes, the development of immunoassays can offer a simple alternative for the specific detection of GSTs. This will allow more accurate monitoring of in vitro or in vivo toxicological studies involving rats or dogs as animal models to predict drug toxicity in humans.
Materials and methods

Purification of GST
Yb1 GST was purified from rat liver by affinity chromatography according to the method of Hayes [27] , with the exception of S-hexyl GSH-sepharose being used instead of GSH-sepharose. The procedure involved homogenisation of the tissue, centrifugation and chromatography using S-hexyl GSH-sepharose. Purity was established by reducing SDS-PAGE [28] and no significant cross-reactivity was observed with the h or y isoforms of rat GST using Western blot analysis [29] . hGST was purified from canine liver obtained from a beagle dog, essentially by GSH-sepharose affinity chromatographic techniques [30] . The liver was homogenised and after centrifugation applied to a GSH affinity column. Purity was established by reducing SDS-PAGE [28] . Using Western blot analysis [29] , minimal cross-reactivity was evident for canine v or yGST isoforms respectively. Protein quantitation was by Coomassie protein assay and also by absorbance measurements at 280 nm.
Antibody production and purification
New Zealand White rabbits were immunised subcutaneously (s.c.) with purified GST, emulsified in Freunds Adjuvant. When the titre was sufficient, the serum was collected and tested for anti-GST specificity by dot blot. IgG present was extracted using Protein A sepharose chromatography. Purified IgG was used for 96-well plate coating and conjugation to horseradish peroxidase, (Yb1 assay) and for conjugation to N-hydroxy-succinimido-biotin (canine hGST assay). A murine monoclonal IgG directed against human hGST exhibited 100% cross-reactivity with canine hGST and was used for 96-well plate coating.
GST enzyme immunoassay
Biotrin Canine hGST EIA and Rat Yb1 EIA are quantitative enzyme immunoassays. Both EIA procedures are based on the sequential addition of sample, conjugate and substrate to 96-well plates pre-coated with anti-GST-IgG. The resultant colour intensity is directly proportional to the amount of GST in the sample (Fig. 2) . The assay ranges are 0-100 vg/l.
Assay validation
The following parameters were evaluated in order to validate the EIAs for GST detection: (1) reproducibility (inter-and intra-assay variation); (2) assay sensitivity; (3) parallelism; (4) sample spiking and recovery.
Results
Antisera raised against both Yb1 and canine hGST was checked for cross-reactivity with other isoforms of rodent and canine GST respectively by Western blot analysis and EIA. Fig. 1A shows Western blot analysis of Yb1, YaYc and Yp, as well as rat liver and kidney homogenates using anti-Yb1 antisera. No significant cross-reactivity was observed with any other major isoform of rodent GST. In the Yb1 immunoassay, no significant cross-reactivity was detected with Yp or YaYc. Fig. 1B similarly shows the specificity of the monoclonal anti-hGST antibody used for plate coating in the canine hGST EIA. No cross-reactivity was observed with any other isoform of canine GST. In the immunoassay, no significant cross-reactivity was detected with canine y or v. The assay sensitivity (i.e. the lowest concentration distinguishable from zero) was determined from the analysis of 30 negative samples in the assay. The concentration corresponding to the optical density (O.D.) of the mean of the 30 negatives plus two standard deviations (S.D.) was deemed to be the lower limit of detection of the assay. For the Yb1 EIA, the sensitivity in the microwell was 0.2 vg/l, corresponding to 2.0 vg/l in a sample diluted 1/10. In the canine aGST EIA, the sensitivity was determined to be 2.1 vg/l in the microwell, corresponding to an initial sample concentration of 10.5 vg/l when assayed at a 1/5 dilution (Table 1) .
Precision was investigated as inter-and intra-assay reproducibility. Inter-assay reproducibility was determined based on the analysis of three samples at concentrations spanning the range of the standard curve, assayed in duplicate, in ten separate assays. Intra-assay reproducibility was calculated from the analysis of three samples at varying concentrations, assayed in ten replicates in the same assay.
In the Yb1 assay, the coefficient of variation (CV) for the mean inter-assay reproducibility over the range of the standard curve was 8.5% (range: 8.3-8.8%) (Table 2A) , while the CV for the mean intra-assay reproducibility was 6.2% (range: 5.1-7.1%) (Table 2B ). In the canine hGST EIA, the CV for the mean inter-assay Canine serum and assay sample diluent were spiked with purified hGST and each assayed at four different dilutions.
reproducibility was 11.5% (range: 6.7-21.2%) (Table 2A) , while the CV for the mean intra-assay reproducibility was 9% (range: 5.1-17.7%) (Table 2B) . Tables 3 and 4 illustrate sample recovery/linearity of dilution in the canine GST assay, whereby the recovery of purified aGST spiked into canine serum was compared to that for assay sample diluent. Mean recovery was 99% (Table 3) . Linearity of dilution of canine hGST was observed in other biological matrices including serum, urine and cell culture media (Table 4) , confirming the compatibility of these matrices in the immunoassay.
The mean recovery of spiked Yb1 into rat urine over a range of concentrations from was 102% (Table 5) Linearity of dilution for Yb1 was observed in tissue homogenates and urine samples (Table 6 ) and no prozone effect was observed up to levels of 3.5 g/l.
The normal range for Yb1 in Sprague Dawley and Wistar rats was established by assaying normal urine samples from 30 Sprague Dawley and 23 Wistar rats. It appears that the normal range of Yb1 differs between different strains of rat. For Sprague Dawley rats, the range was 5-65 vg/l, while for Wistar rats a range of 3-30 vg/l was observed. There does not however appear to be any difference between the levels of Yb1 in urine from female and male rats.
The utility of the canine hGST EIA in measuring hepatic damage has been investigated (Fig. 3) . Following warm ischemic damage to the liver in adult beagle dogs, serum hGST levels were measured and compared to the traditional transaminases (GOT and GPT). GST levels showed an initial peak greater than either of Table 4 Detection and quantitation of canine hGST which was spiked into a variety of matrices including serum, urine and tissue culture medium (M.E.M. and TC-100) High samples were spiked with 30 vg/l Yb1, and low samples were spiked with 100 vg/l Yb1. The mean recovery was 102%.
the other enzymes, and also exhibited a more rapid normalisation than the transaminases [31] . This pattern is similar to that observed in studies of liver damage in humans. The canine hGST EIA was also used to quantify hGST as a percentage of total soluble protein in canine liver cytosol (3.1%), and in the MDCK cell line (3.87 ng/10 6 cells).
Conclusions
Enzyme immunoassays have been developed for the quantitative determination of canine hGST and rodent vGST (Yb1) in various biological matrices [31, 32] . The assays are performed at room temperature and can be completed within 3 h. Multiple sample analysis is possible. Validation studies have shown that canine hGST and rodent Yb1 can be accurately and precisely determined using the respective enzyme immunoassay and that changes in the levels of GSTs are detectable.
GST Yb1 has been located to the distal convoluted tubule of the rat kidney, whereas YaYc (hGST) has been found in the proximal as well as the distal tubule [19] . Any event which precipitates distal tubule damage in the rat kidney may cause an increase in urinary Yb1 levels, and a number of nephrotoxic agents have been Table 6 Linearity of dilution of samples in the rat Yb1 EIA shown to increase urinary Yb1 concentrations [22, 23] . The measurement of Yb1 in urine has been predicted as an excellent indicator of nephrotoxicity or kidney damage caused by cisplatin [21] . Thus, by the simultaneous measurement of YaYc and Yb1, it may be possible to identify and differentiate between damage to the proximal and distal tubules in the rat kidney.
Elevated levels of canine hGST, present after hepatic injury, are detectable demonstrating the utility of the technique for monitoring in vivo hepatic status. With the concerted efforts to find alternative methods to animal testing for new drugs, the focus is turning to in vitro model systems. The ability to study the effects of novel compounds on primary cells, cell lines or tissue slices grown in static or perfusion cultures will play a pivotal role in these new testing methods. Hepatocytes and renal cells in particular will form the basis of studying the hepato-and nephro-toxic properties of new pharmaceuticals. Because of the specific localisation of GSTs in both of these cell types, the monitoring of GSTs will provide critical information on the status of the cells in any culture system. Indeed studies have already shown that GSTs can be used as markers of cell viability of human liver and kidney slices in an in vitro system, as well as markers for drug-induced toxicity [33, 34] .
Another important implication of these tests is the ability to distinguish between organ damage in two inter-connected animal model systems. Because of the high level of specificity of the rodent and porcine EIAs, no cross-reactivity was observed between the same class of GSTs from different animal species. For example, bioartificial livers (BAL) containing isolated porcine hepatocytes were connected to rats with liver ischemia [35] . By simultaneously monitoring plasma for rodent and porcine hGST, it was possible to differentiate between damage caused to the rodent liver and to the porcine hepatocytes in the BAL. While rodent hGST levels peaked at 6 h of liver ischemia and gradually decreased at 14 h, no increase in porcine hGST was detected during this time. It was therefore possible to determine that the hepatocytes in the BAL were not effected by the damage caused to the rodent liver and the BAL was capable of maintaining pig hepatocyte integrity in vivo over a period of 14 h.
The necessity of animal toxicity testing of new therapeutics and drugs requires the availability of validated, reliable, easy to use and sensitive tests. GSTs have proved to be sensitive markers of organ and tissue damage caused by a wide range of harmful substances. The easy availability of rapid, easy to use, reliable tests to monitor GSTs in a variety of biological matrices, from a range of animal models facilitates the study of both in vivo and in vitro systems.
